Insights · Tag
Overdose Prevention
More than 100,000 Americans die of drug overdoses each year — under prohibition, not because of reform. Overdose prevention is regulated supply, fentanyl testing, naloxone access, and reentry protocols that treat the first 72 hours after release as a medical emergency.
-
Drug Legalization Series Part 25: Punishing Pain or Saving Lives — The Real Choice in Drug Policy Reform
Part 25 reframes drug policy as punishing pain or saving lives: public health, overdose prevention, treatment on demand, and risk-based regulation.
-
Drug Legalization Series Part 24: The Ethical Case for Regulation — What We Owe People We Know Will Use Drugs
Part 24 on drug legalization ethics: we owe regulation that cuts preventable death instead of outsourcing safety to a black market when use is inevitable.
-
Drug Legalization Series Part 23: What Failure Looks Like If We Don't Change: Projecting the Status Quo Forward
Part 23 models drug overdose death projections under today's laws, showing what failure may look like if we keep the status quo.
-
Drug Legalization Series Part 22: Public Buy-In Is Built, Not Waited For: How Public Opinion Actually Shifts on Uncomfortable Drug Policy
How leaders build public support for drug policy that feels uncomfortable first — and why public perception shapes what lawmakers pass and fund.
-
Drug Legalization Series Part 21: Drug Legalization Is Bipartisan: Political Reality, Not Political Fantasy
Part 21 explains why bipartisan drug policy reform is viable now and why regulated legalization is a public health and safety upgrade, not ideology.
-
Drug Legalization Series Part 20: Urgency Without Panic — Why This Can't Wait Another Decade
Part 20 explains why an overdose prevention strategy can't wait another decade, and lays out urgent, measurable steps that reduce death without panic.
-
Drug Legalization Series Part 19: This Is Already Being Administered — The Myth That Regulation Is Too Complex to Run
Part 19 argues regulation is already administered across health, safety, and controlled-substance systems — and how that capacity can scale responsibly.
-
Drug Legalization Series Part 18: Public Health, Not Moral Panic — Building a Public Health Drug Policy That Actually Reduces Harm
Part 18 makes the case for public health drug policy that replaces moral panic with overdose prevention, harm reduction, and treatment on demand.
-
Drug Legalization Series Part 17: Case Studies Without Cherry-Picking — What Worked, What Failed, and Why
Part 17 reviews drug decriminalization case studies across the U.S. and abroad to show what worked, what failed, and why — without cherry-picking.
-
Drug Legalization Series Part 12: The Reentry Window We Keep Wasting
Prison release overdose risk peaks in days and weeks after release. Which programs actually cut overdose, recidivism, and instability.
-
Drug Legalization Series Part 6: Tusi (Pink Cocaine), Xylazine, and THC Analogues: Why Enforcement Can’t Keep Up
Tusi, xylazine, medetomidine, nitazenes, and THC analogues prove enforcement can't keep up. Regulation creates testing, labeling, and accountability.
-
Drug Legalization Series Part 1: Drug Legalization Isn’t Endorsement. It’s Regulation and Harm Reduction.
Drug legalization isn’t endorsement. Part 1 explains why punishment fails, why reentry is deadly, and why harm reduction saves lives.